Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum

Microbial Pathogenesis

Volumn 21, Issue 2, 1996, Pages 125-137

  Aaberge, Ingeborg S ^a   Hvalbye, Benedicte ^a   Løvik, Martinus ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

human serum; mice; passive immunization; protection; serotype 6B; Streptococcus pneumoniae

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTEREMIA; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALIA; BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030219773     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.1996.0048     Document Type: Article

References (26)

1. 1. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82: 445-64.
2. 2. Musher DM, Johnson Jr B, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990; 58: 3871-6.
3. 3. Aaberge IS, Eng J, Lermark G, Løvik M. Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum. Microbial Pathogen 1995; 18: 141-52.
4. 4. Yother J, Forman C, Gray BM, Briles DE. Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun 1982; 36: 184-8.
5. 5. McDaniel LS, Waltman II WD, Gray B, Briles DE. A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog 1987; 3: 249-60.
6. 6. Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin Jr WH, McDaniel LS, Eldridge J, Brooks J. Antipneumococal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 1989; 57: 1457-64.
7. 7. Nielsen SV, Sørensen UBS, Henrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog 1993; 14: 299-305.
8. 8. Briles DE, Claffin JL, Schroer K, Forman C. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 1981; 294: 88-90.
9. 9. Austrian R. Preventing pneumococcal infection. In: Norrby E, Brown F, Chanock RM, Ginsberg HS, eds. Vaccines 94. Modern Approaches to new vaccines including prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994: 91-8.
10. 10. Chudwin DS. Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model. Clin Immunol Immunopathol 1989; 50: 62-71.
11. 11. Jorgensen JH, Howell AW, Maher LA, Facklam RR. Serotypes of respiratory isolates of Streptococcus pneumoniae compared with the capsular types included in the current pneumococcal vaccine. J Infect Dis 1991; 163: 644-6.
12. 12. Nielsen SV, Henrichsen J. Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982-1987. Clin Infect Dis 1992; 15: 794-8.
13. 13. Sessegolo JF, Levin ASS, Levy CE, Asensi M, Facklam RR, Teixeira LM. Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated in Brazil from 1988-1992. J Clin Microbiol 1994; 906-11.
14. 14. Hedlund J, Svenson SB, Kalin M, Henrichsen J, Olsson-Liljequist B, Möllerberg G, Källenius G. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clin Infect Dis 1995; 21: 948-53.
15. 15. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31.
16. 16. Griffiss JM, Bertram MA. Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the coarse of invasive disease. J Infect Dis 1977; 136: 733-9.
17. 17. Musher DM, Goree A, Baughn RE, Birdsall HH. Imunoglobulin A from bronchopulmonary secretions blocks bactericidal and opsonizing effects of antibody to nontypable Haemophilus influenzae. Infect Immun 1984; 45: 36-40.
18. 18. Goodner K, Horsfall Jr. FL. The protective action of type I antipneumococcus serum in mice. J Exp Med 1935; 62: 359-74.
19. 19. Winkelstein JA. Complement and the host's defense against the pneumococcus. Critical Reviews in Microbiol 1984; 11: 187-208.
20. 20. Hosea SW, Brown EJ, Frank MM. The critical role of complement in experimental pneumococcal sepsis. J Infect Dis 1980; 142: 903-9.
21. 21. Brown EJ, Hosea SW, Frank MM. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis 1983; 5: S797-S805.
22. 22. Nowicki S, Martens MG, Nowicki BJ. Gonococcal infection in a nonhuman host is determined by human complement C1q. Infect Immun 1995; 63: 4790-41.
23. 23. Felton LD. The correlation of the protective value with the titers of other antibodies in type I antipneumococcus serum. J Immunol 1931; 21: 341-56.
24. 24. Walter AW, Schenkein EL, Sutliff WD. Mouse-protective titers of sera of volunteers following injection of pneumococci or their type-specific polysaccharides. J Exp Med 1946; 83: 321-8.
25. 25. Lund E, Henrichsen J. Methods in Microbiology, London. Academic Press. 1978; 12: 243.
26. 26. Aaberge IS, Michaelsen TE, Rolstad AK, Groeng E-C, Solberg P, Løvik M. SCID-Hu mice immunized with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection. Infect Immun 1992; 60: 4146-53.